ATNXQ — Athenex Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.13m
- $74.91m
- $102.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.03% | ||
| Return on Equity | -439.12% | ||
| Operating Margin | -71.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 89.1 | 101.23 | 144.39 | 95.37 | 102.82 | 102.99 | 106.95 | 22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
Directors
- Johnson Lau CHM (47)
- Steven Adams CFO (53)
- William Zuo CEX (59)
- Jeffrey Yordon COO (72)
- Teresa Bair SVP (50)
- Timothy Cook OTH (59)
- Rudolf Kwan OTH (68)
- A. Kim Campbell LED (74)
- Manson Fok DRC (64)
- Stephanie Davis IND (57)
- Jordan Kanfer IND (51)
- Robert Spiegel IND (71)
- Kwan Hung Tsang IND (56)
- John Vierling IND (74)
- Jinn Wu IND (72)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- November 4th, 2003
- Public Since
- June 14th, 2017
- No. of Shareholders
- 121
- No. of Employees
- 269
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,663,209
- Address
- 1001 Main St Ste 600, BUFFALO, 14203-1009
- Web
- https://www.athenex.com/
- Phone
- +1 7168988625
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ATNXQ
Similar to ATNXQ
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Athenex share price?
As of Today at 01:03 UTC, shares in Athenex are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Athenex share price performed this year?
Shares in Athenex last closed at $0.00 and the price had moved by -99.98% over the past 365 days. In terms of relative price strength the Athenex share price has underperformed the S&P500 Index by -99.98% over the past year.
What are the analyst and broker recommendations for Athenex?
The overall consensus recommendation for Athenex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Athenex dividend yield?
Athenex does not currently pay a dividend.
Does Athenex pay a dividend?
Athenex does not currently pay a dividend.
When does Athenex next pay dividends?
Athenex does not currently pay a dividend.
How do I buy Athenex shares?
To buy shares in Athenex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Athenex?
As of the previous close price of $0.00, shares in Athenex had a market capitalisation of $0.05m.
Where are Athenex shares listed?
Here are the trading details for Athenex:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ATNXQ
What kind of share is Athenex?
Based on an overall assessment of its quality, value and momentum Athenex is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Athenex share price forecast for 2023?
The analyst consensus target price for shares in Athenex is $1.23. That is 40883.61% above the last closing price of $0.00.
Analysts covering Athenex currently have a consensus Earnings Per Share (EPS) forecast of -$4.50 for the next financial year.
Find out moreWhat is the trend in the Athenex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athenex. Over the past six months, its share price has underperformed the S&P500 Index by -99.92%.
As of the last closing price of $0.00, shares in Athenex were trading -99.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Athenex PE Ratio?
The Athenex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Athenex?
Athenex's management team is headed by:
- Johnson Lau - CHM
- Steven Adams - CFO
- William Zuo - CEX
- Jeffrey Yordon - COO
- Teresa Bair - SVP
- Timothy Cook - OTH
- Rudolf Kwan - OTH
- A. Kim Campbell - LED
- Manson Fok - DRC
- Stephanie Davis - IND
- Jordan Kanfer - IND
- Robert Spiegel - IND
- Kwan Hung Tsang - IND
- John Vierling - IND
- Jinn Wu - IND